Minimum 5-year follow-up after Cormet hip resurfacing. A single surgeon series of 234 hips.

The performance of the Cormet hip resurfacing device was evaluated after a minimum of 5 years in 234 hips. The mean age of the patients was 54 years; there were 135 men and 80 women. The primary diagnosis was osteoarthritis in 78% of the patients. Outcome measures were the Harris Hip Score and implant survival. The overall survival rate was 94% with 12 revisions in women and 3 in men. There were 7 femoral and 5 acetabular failures and two revisions for groin pain. Cumulative survival rate in men and women was 98% and 89%, in patients with a femoral component larger than 44 mm and smaller than 44 mm 97% and 89% respectively. Patients with primary osteoarthritis had a 95% cumulative survival rate at 5 years. The risk of failure was 6.4 times higher in women than in men. Our results suggest that hip resurfacing with the Cormet device is an acceptable alternative for active patients with hip arthritis, but patient selection is crucial for good long-term results.